Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neurobiology of Aging

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.NEUROBIOLAGING.2005.06.015PMID 16183170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span.

  2005cited by this paper
• Role of insulin-like growth factor I signaling in neurodegenerative diseases

  2004cited by this paper
• Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase

  2004cited by this paper
• Insulin-like growth factor I and Alzheimer´s disease: therapeutic prospects?

  2004cited by this paper
• Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer's disease.

  2004cited by this paper
• Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration.

  2004cited by this paper
• Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.

  2004cited by this paper
• PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation

  2003cited by this paper
• Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease.

  2003cited by this paper
• Epidemiology of neurodegeneration.

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Serum insulin-like growth factor I regulates brain amyloid-beta levels.

  2002cited by this paper
• Gene Expression Profiles of Cholinergic Nucleus Basalis Neurons in Alzheimer's Disease

  2002cited by this paper
• Disruption of neurotransmission in Drosophila mushroom body blocks retrieval but not acquisition of memory

  2001cited by this paper
• Dynamin Isoform-specific Interaction with the Shank/ProSAP Scaffolding Proteins of the Postsynaptic Density and Actin Cytoskeleton*

  2001cited by this paper
• Circulating Insulin-Like Growth Factor I Mediates the Protective Effects of Physical Exercise against Brain Insults of Different Etiology and Anatomy

  2001cited by this paper
• Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease

  2001cited by this paper
• Clearing the brain's amyloid cobwebs.

  2001cited by this paper
• Modulating astrogliosis after neurotrauma

  2001cited by this paper
• New developments in animal models of Alzheimer’s disease

  2001cited by this paper
• Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation.

  2000cited by this paper
• Insulin-like Growth Factor-I Stimulates Dephosphorylation of IκB through the Serine Phosphatase Calcineurin (Protein Phosphatase 2B)*

  2000cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Superior Water Maze Performance and Increase in Fear-Related Behavior in the Endothelial Nitric Oxide Synthase-Deficient Mouse Together with Monoamine Changes in Cerebellum and Ventral Striatum

  2000cited by this paper
• Demonstration of a Coupled Metabolism–Efflux Process at the Choroid Plexus as a Mechanism of Brain Protection Toward Xenobiotics

  1999cited by this paper
• Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

  1999cited by this paper
• Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

  1999cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia.

  1998cited by this paper
• Astrogliosis in the Neonatal and Adult Murine Brain Post-Trauma: Elevation of Inflammatory Cytokines and the Lack of Requirement for Endogenous Interferon-γ

  1997cited by this paper
• The 'amyloid cascade hypothesis' of AD: decoy or real McCoy?

  1997cited by this paper
• The 'amyloid cascade hypothesis' of AD: decoy or real McCoy?

  1997cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier.

  1996cited by this paper
• An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

  1994cited by this paper
• Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

  1990cited by this paper
• Developments of a water-maze procedure for studying spatial learning in the rat.

  1984cited by this paper
• Disruption of neurotransmission in Drosophila mushroom body blocks retrieval but not acquisition of memory

  year unknowncited by this paper

• Insulin-like growth factor 1 associated research in Alzheimer’s disease: an exploratory trends analysis

  2026cites this paper
• Phosphoproteomics Analysis of Insulin-like Growth Factor-1 Signaling in Neuronal Cells.

  2026cites this paper
• Modulatory Action of Insulin-like Growth Factor I (IGF-I) on Cortical Activity: Entrainment of Metabolic and Brain Functions

  2025cites this paper
• Resistance training‐induced adaptations in the neuromuscular system: Physiological mechanisms and implications for human performance

  2025cites this paper
• Uncovering the intricacies of IGF-1 in Alzheimer’s disease: new insights from regulation to therapeutic targeting

  2025cites this paper
• Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis

  2025cites this paper
• Accumulating the key proteomic signatures associated with delirium: Evidence from systematic review

  2024cites this paper
• Identification of IGF-1 Effects on White Adipose Tissue and Hippocampus in Alzheimer’s Disease Mice via Transcriptomic and Cellular Analysis

  2024cites this paper
• Role of the Insulin-like Growth Factor System in Neurodegenerative Disease

  2024cites this paper
• The IGF System and Aging

  2024cites this paper
• Gene deletion of Pregnancy-associated Plasma Protein-A (PAPP-A) improves pathology and cognition in an Alzheimer's disease mouse model.

  2024cites this paper
• Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies

  2024cites this paper
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice

  2024cites this paper
• IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson’s disease models

  2023cites this paper
• Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome

  2023cites this paper
• Cyclic Glycine-Proline Improves Memory and Reduces Amyloid Plaque Load in APP/PS1 Transgenic Mouse Model of Alzheimer's Disease

  2023cites this paper
• The neurobiology of insulin-like growth factor I: From neuroprotection to modulation of brain states

  2023cites this paper
• Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

  2022cites this paper
• Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity

  2022cites this paper
• Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.

  2022cites this paper
• From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy

  2021cites this paper
• Physical Exercise Modulates Brain Physiology Through a Network of Long- and Short-Range Cellular Interactions

  2021cites this paper
• Insulin‐like growth factor 1 gene transfer for sporadic Alzheimer's disease: New evidence for trophic factor mediated hippocampal neuronal and synaptic recovery‐based behavior improvement

  2021cites this paper
• The Involvement of Insulin-Like Growth Factor 1 and Nerve Growth Factor in Alzheimer’s Disease-Like Pathology and Survival Role of the Mix of Embryonic Proteoglycans: Electrophysiological Fingerprint, Structural Changes and Regulatory Effects on Neurotrophins

  2021cites this paper
• Peptides Derived from Growth Factors to Treat Alzheimer’s Disease

  2021cites this paper
• Biomarkers in delirium: A systematic review.

  2021cites this paper
• Physical Exercise-Induced Myokines in Neurodegenerative Diseases

  2021cites this paper
• The brain as an insulin-sensitive metabolic organ

  2021cites this paper
• Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions

  2021cites this paper
• Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: a systematic review.

  2021cites this paper
• Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks

  2021cites this paper
• Brain insulin, insulin‐like growth factor 1 and glucagon‐like peptide 1 signalling in Alzheimer’s disease

  2021cites this paper
• Local autocrine signaling of IGF1 synthesized and released by CA1 pyramidal neurons regulates plasticity of dendritic spines

  2021cites this paper
• Role of IGF-1 in neuroinflammation and cognition deficits induced by sleep deprivation.

  2021cites this paper
• IGF-1/GLP-1 Signaling Activator 4-hydroxyisoleucine (4-HI) Prevent Neurobehavioral and Neurochemical Defects in Methylmercury-induced Experimental Model of ALS: Insights From CSF, Blood Plasma and Brain Homogenate Samples in Rats

  2021cites this paper
• DIET INFLUENCES PERIPHERAL AMYLOID β METABOLISM: A ROLE FOR CIRCULATING INSULIN-LIKE GROWTH FACTOR I

  2020cites this paper
• Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?

  2020cites this paper
• Circulating Insulin-Like Growth Factor I is Involved in the Effect of High Fat Diet on Peripheral Amyloid β Clearance

  2020cites this paper
• Blending Established and New Perspectives on Choroid Plexus-CSF Dynamics

  2020cites this paper
• Role of the Choroid Plexus in Health and Disease

  2020cites this paper
• Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

  2020cites this paper
• Effective Approach to Improving Cognitive Function in the Elderly: Focused on Cognitive-exercise Combination Program

  2020cites this paper
• Circulating insulin-like growth factor I is involved in the effect of diet on peripheral amyloid β clearance

  2020cites this paper
• The Role of Neurovascular System in Neurodegenerative Diseases

  2020cites this paper
• Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients

  2020cites this paper
• Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events

  2019cites this paper
• Editorial: Cognitive and Brain Aging: Interventions to Promote Well-Being in Old Age

  2019cites this paper
• The role of Insulin-like Growth Factors (IGFs) and IGF-binding proteins in the nervous system

  2019cites this paper
• Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model

  2019cites this paper
• Editorial: Cognitive and Brain Aging: Interventions to Promote Well-Being in Old Age

  2019cites this paper
• The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins in the Nervous System

  2019cites this paper
• Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer’s Disease

  2019cites this paper
• 40 YEARS of IGF1 IGF1: the Jekyll and Hyde of the aging brain

  2018cites this paper
• IGF-I Gene Therapy in Aging Rats Modulates Hippocampal Genes Relevant to Memory Function

  2018cites this paper
• Physical Exercise Enhances Neuroplasticity and Delays Alzheimer’s Disease

  2018cites this paper
• 40 YEARS of IGF1: IGF1: the Jekyll and Hyde of the aging brain.

  2018cites this paper
• Hormones of energy homeostasis : linking weight loss and cognition in Parkinson's disease?

  2018cites this paper
• Downregulation of circulating insulin-like growth factor 1 contributes to memory impairment in aged mice after sevoflurane anesthesia

  2017cites this paper
• Neurotrophic and Neuroregenerative Effects of GH/IGF1

  2017cites this paper
• Growth Hormone Replacement Therapy in Patients without Adult Growth Hormone Deficiency: What Answers Do We Have So Far?

  2017cites this paper
• Therapeutic potential of IGF-I on hippocampal neurogenesis and function during aging

  2017cites this paper
• Obesity and neuroinflammatory phenotype in mice lacking endothelial megalin

  2017cites this paper
• Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative review.

  2017cites this paper
• IGF-1: an endogenous link between traumatic brain injury and Alzheimer disease?

  2017cites this paper
• A variant in PPP4R3A protects against alzheimer‐related metabolic decline

  2017cites this paper
• Insulin‐like growth factor‐1 protects SH‐SY5Y cells against &bgr;‐amyloid‐induced apoptosis via the PI3K/Akt‐Nrf2 pathway

  2017cites this paper
• Lack of Association between Pre-Operative Insulin-Like Growth Factor-1 and the Risk of Post-Operative Delirium in Elderly Chinese Patients

  2016cites this paper
• Insulin‐like growth factor‐I gene therapy increases hippocampal neurogenesis, astrocyte branching and improves spatial memory in female aging rats

  2016cites this paper
• The Choroid Plexus in Healthy and Diseased Brain

  2016cites this paper
• The Effects of the Woorichum Exercise on Metabolic Syndrome Risk Factors, Brain Growth Factor in Obese Elderly Women According to Sasang Constitution

  2016cites this paper
• Partial IGF-1 deficiency induces brain oxidative damage and edema, which are ameliorated by replacement therapy.

  2016cites this paper
• MicroRNA ‐ 26 b is upregulated in a double transgenic mouse model of Alzheimer ' s disease and promotes the expression of amyloid ‐ β by targeting insulin ‐ like growth factor 1

  2016cites this paper
• Relación del Control Glucémico, Función Cognitiva y las Funciones Ejecutivas en el Adulto Mayor con Diabetes Tipo 2: Revisión Sistemática Relation of the Glycemic Control, Cognitive Function and Executive Function in the Elderly with Type 2 Diabetes: Systematic Review

  2016cites this paper
• The intersection between growth factors, autophagy and ER stress: A new target to treat neurodegenerative diseases?

  2016cites this paper
• Insulin-like peptides signaling in Alzheimer's disease: on the road to alternative therapeutics

  2016cites this paper
• MicroRNA-26b is upregulated in a double transgenic mouse model of Alzheimer's disease and promotes the expression of amyloid-β by targeting insulin-like growth factor 1.

  2016cites this paper
• The Benefits of Exercise and Metabolic Interventions for the Prevention and Early Treatment of Alzheimer's Disease.

  2016cites this paper
• Relación del Control Glucémico, Función Cognitiva y las Funciones Ejecutivas en el Adulto Mayor con Diabetes Tipo 2: revisión Sistemática

  2016cites this paper
• Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer’s Disease

  2016cites this paper
• The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice.

  2016cites this paper
• Chapter 33 – The Mechanisms of Insulin Action

  2016cites this paper
• Neurotrophic uncoupling of IGF-1 in Alzheimer’s disease: translation into early diagnosis and involvement of lifestyle risk factors

  2015influential citation
• Role of physical and mental training in brain network configuration

  2015cites this paper
• Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration.

  2015cites this paper
• Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer’s Disease Prevention and Early Intervention

  2015cites this paper
• Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed.

  2015cites this paper
• Multiple system atrophy : a translational approach Characterization of the insulin/IGF-1 signaling pathway

  2015cites this paper
• Off-label use of hormones as an antiaging strategy: a review

  2014cites this paper
• Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats

  2014cites this paper
• Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice

  2014cites this paper
• Factors associated with Cognitive Decline in the Elderly in Community

  2014cites this paper
• Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders.

  2014cites this paper
• IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity

  2014cites this paper
• Insulin Action in Brain Regulates Systemic Metabolism and Brain Function

  2014cites this paper
• Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?

  2014influential citation
• The proline-rich hypothalamic peptide is a modulator of functions of neurotrophins and neuronal activity in amyloid-induced neurodegeneration

  2014cites this paper
• Amyloid Beta-Mediated Epigenetic Alteration of Insulin-Like Growth Factor Binding Protein 3 Controls Cell Survival in Alzheimer's Disease

  2014cites this paper
• Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease

  2014cites this paper
• Gene therapy and cell reprogramming for the aging brain: achievements and promise.

  2014cites this paper
• Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model.

  2014cites this paper